INMB
HEALTHCAREINmune Bio Inc
$1.52-0.02 (-1.30%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INMB Today?
No stock-specific AI insight has been generated for INMB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.09$8.29
$1.52
Fundamentals
Market Cap$40M
P/E Ratio—
EPS$-1.86
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume409K
Avg Volume (10D)—
Shares Outstanding26.6M
INMB News
20 articles- INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business UpdateYahoo Finance·May 7, 2026
- INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory DiseasesYahoo Finance·May 5, 2026
- INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thYahoo Finance·Apr 30, 2026
- INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer ModelsYahoo Finance·Apr 16, 2026
- INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash WiselyYahoo Finance·Apr 1, 2026
- INmune Bio, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesYahoo Finance·Mar 31, 2026
- INmune Bio Inc. Announces 2025 Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.Yahoo Finance·Mar 24, 2026
- INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s DiseaseYahoo Finance·Mar 19, 2026
- INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s WebinarYahoo Finance·Feb 23, 2026
- INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEBYahoo Finance·Feb 19, 2026
- INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s DiseaseYahoo Finance·Feb 12, 2026
- INmune Bio submits pre-submission package for CORDStrom with MHRAYahoo Finance·Feb 11, 2026
- INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEBYahoo Finance·Feb 10, 2026
- INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic InitiativesYahoo Finance·Jan 27, 2026
- Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ PlatformYahoo Finance·Dec 5, 2025
- INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's PatientsYahoo Finance·Dec 1, 2025
- INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD ConferenceYahoo Finance·Nov 18, 2025
- INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock NowYahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.54
Day High$0.00
Day Low$0.00
52 Week High$8.29
52 Week Low$1.09
52-Week Range
$1.09$8.29
$1.52
Fundamentals
Market Cap$40M
P/E Ratio—
EPS$-1.86
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume409K
Avg Volume (10D)—
Shares Outstanding26.6M
About INmune Bio Inc
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—